Ed Saltzman
Executive Chairman, Cello Health BioConsulting, USA

Mr. Ed Saltzman is Executive Chairman of Cello Health BioConsulting (CHBC), previously Defined Health, after having led the sale of Defined Health to Cello Health in 2017. CHBC is a leading strategic business development advisory firm that serves senior executives in pharma, biotech, and investment sectors in the US, Europe, Japan/Asia, and Israel. Ed possesses a vast knowledge of the pharmaceutical and biotechnology industry accumulated over 25+ years of consultancy at Defined Health to pharma, biotech, specialty pharma, and investors. From this breadth and depth of experience, he provides guidance to CHBC’s senior project leadership that works with clients across multiple therapeutic areas. 

Mr. Saltzman is a well-regarded and in-demand speaker on industry issues and has been recognized widely as an early “spotter” of key trends that go on to have significant impact within the life sciences industry, especially those that pertain to the licensing and business development field. He has spoken over the past 20 years to large audiences at Defined Health’s Therapeutic Insight and Cancer Progress conferences, the Licensing Executives Society Annual Meeting, and numerous industry conferences. In addition to these public events, Mr. Saltzman has presented targeted strategy briefings and held discussions privately with scores of boards of directors, executive management committees, and licensing and business development teams at large pharma, specialty pharma, and biotech companies, as well with the leading life sciences venture capital firms. He notably coined the term “Proof of Relevance” to describe indisputable demonstration of clinical and economic value in drug development.  He is a recent recipient of the LES Frank Barnes Mentoring Award for his contributions to education in the life sciences sector. 

Ed held prior positions at the Ayerst Laboratories unit of American Home Products, where he was responsible for evaluating and forecasting compounds being considered for licensing, and at FIND/SVP, where he managed the Healthcare Information Center.

Ed serves as a Venture Advisor to the Israel Biotech Fund, is on the Board of Directors of Vidac Pharma, and is a member of the Licensing Executives Society (LES) and the New York Pharma Forum. He is a graduate of New York University.

 
​ 
See the Speaker List